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Multi-center randomized open label phase II trial 
on three rituximab dosing schemes in immune
thrombocytopenia patients
The overall short-term treatment efficacy of rituximab
(R) in immune thrombocytopenia (ITP) is reported to be
approximately 58%.1,2 With four once-weekly 375 mg/m2
doses, responses of 31% after two years,2 and 21% after
five years2 can be expected with a median clinical improve-
ment time of 10.51 months, and up to 49 months in other
studies.3 Since lower doses have comparable efficacy,4 R
remains an attractive second-line therapy especially in
patients where splenectomy is contraindicated or should be
delayed.1,3,5-8
However, there are no known response-modifying fac-
tors that can provide an optimal basis for choosing R and
its dosing. Moreover, while numbers of ITP patients are
limited, knowledge on these issues is mainly derived from
(clustered) often small-sized and non-randomized studies.1-
3,5,9 Therefore, in order to, firstly, delineate the efficacy and
safety of two alternative dosing strategies, and secondly, to
study the R-response-modifying factors (RMF), the Dutch
Hemato-Oncology Cooperative Group (HOVON) random-
ized 156 immune thrombocytopenia (ITP) patients
between four once-weekly standard 375 mg/m2 doses (arm
A), a 2-weekly 375 mg/m2 in early responding patients (arm
B), and a 2-weekly 750 mg/m2 regimen (arm C). In more
detail, in arm B, when no early (at day 15) response was
present or when response was lost within six weeks,
another two once-weekly 375 mg/m2 rituximab infusions
were given. 
Eligible patients needed to be 18 years of age or older and
with an ITP relapse or refractoriness (at least 2 platelet
counts less than 30x109/L) and at least three weeks after
high-dose corticosteroids (≥ 1mg/kg) before start of R (R
start); further study details are available in the Online
Supplementary Appendix. Complete (CR) good/partial (PR)
and moderate (MR) response were defined as platelet
counts of 150x109/L or more and 50x109/L or more on 2
consecutive occasions and a platelet count over 30x109/L
with at least twice the base-line count, respectively.
Retrospectively, responses were also analyzed according to
the International Working Group (IWG) ITP trial guide-
lines.10 Relapse was defined as a further fall in platelet count
to below 30x109/L or below the 2-fold increase of base-line
platelet count. Relapse-free survival (RFS), defined as time
from response until relapse, emergency treatment, or
death, was analyzed using the actuarial Kaplan-Meier
method. Patients still alive at the date of last contact were
censored. The primary objective of this study was to eval-
uate the individual treatment arms as sufficiently promising
(CR+ PR + MR > 50%) strategies11 but not to compare the
results between the treatment arms. All analyses were per-
formed according to the intention-to-treat principle, irre-
spective of patients' compliance. Ineligible patients were
excluded from all analyses. With 15 patients considered
ineligible, and 3 patients who did not start with their
assigned R treatment, 138 patients were evaluated for
response as primary end point (Table 1). 
Twelve patients (9%) went off treatment for various rea-
sons. In 4 of these, this was related to R-attributed adverse
events and toxicity; one patient in arm B experienced a life-
threatening infection. Four patients received emergency
treatments (for details see Online Supplementary Table S1
and Figure S1). Weekly platelet counts were taken in all
patients, up to ten weeks (day 71), after which responders
were subsequently monitored monthly for at least 12
months. The median follow up of responding patients was
24 months (range 2-68; with 85% of responders monitored
for >12 months).
As far as R-efficacy is concerned (Table 2), 68 (49 %)
patients responded within ten weeks (19% CR, 20% PR,
11% MR); in 16 of these patients, the response even
improved after ten weeks. Response results were similar:
52% for arm A (39%-65%; 90% confidence intervals),
47% for arm B (33%-60%), and 49% for arm C (37%-
62%). Of 43 patients in arm B, 7 (16%) responded early
and received two 375 mg/m2 doses. Application of IWG
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Table 1. Patients’ characteristics. 
Arm A Arm B Arm C 
(n=46) (n=43) (n=49)
Dose received (mg/m2) 4x375 2 or 4x375 2x750 
Male/female (%) 41/59 47/53 45/55
Age in years, median (range) 56 (18-77) 51 (18-80) 53 (17-82)
WHO 0/1/2/not reported  (%) 85/11/-/4 91/9/-/- 82/16/2/-
Months between ITP diagnosis 11.7 21.8 14.1
and rituximab start, median (range) 0.2-212 0.5-324 0.8-377
On stable or decreasing 41 49 35
corticosteroids at R-start (%)
Splenectomized (%) 2 14 10 
Base-line platelet count 
x109/L, median (range) 14 (3-36) 19 (2-38) 15 (1-30)
R: rituximab.
Table 2. Treatment outcomes.
Treatment outcome (%) Arm A (n=46) Arm B (n=43) Arm C (n=49)
4x375 mg/m2 2 or 4x375 mg/m2 2x750 mg/m2
Best response within 70 days
Total responders: n (%) 24 (52) 20 (47) 24 (49)
CR 10 (22) 7 (16) /5 after 2 doses 9 (18)
PR 9 (20) 8, (19)/ 2 after 2 doses 10 (20)
MR 5 (11) 5 (12) /1 after 2 doses 5 (10)
IWG total response 29 (63) 22 (51) 30(61)
IWG CR 19 (41) 12 (28) 15 (31)
IWG R 10 (22) 10 (23) 15 (31)
Response period 
Days between R start and 22 (3-66) 21 (1-70) 16 (5-59) 
initial response, median (range)
Response ≤ 14 days n (%) 9 (20) 7 (16) 12 (24)
% fast response 38 % 35 % 50%
of all responders
Days between R start and  (range)52 (7-223) 49 (1-364) 48 (14-183) 
best response, median
DFS from CR at 2 years 89% 43% 76% 
Observed relapses in fu 10 11 11
Best response of initial responders from day 70
CR as best response in fu 13 9 11 
PR as best response in fu 9 8 12 
MR as best response in fu 1 3 1 
Relapse * 1 0 0
One patient relapsed after response within 70 days. 
response criteria defining CR as platelet counts above
100x109/L and ‘Response’ combining CR and PR (present in
at least 2 measurements one week apart) led to even higher
response rates: 63% (50%-75%), 59% (38%-64%), and
61% (48%-73%). Overall, responding patients showed a
72% RFS at one year and 58% at two years, and a median
relapse-free survival of 29 months; comparisons between
arms are, however, precluded by group patient numbers
(Figure 1).
As response-modulating factors (RMF) studied through-
out the 3 arms, early response (within 14 days vs. >14
days), showed more CRs within 70 days (18 of 28 vs. 8 of
40; P<0.001) and thereafter (19 of 28 vs.  14 of 40; P=0.01),
but response duration and RFS were similar. Disease dura-
tion defined as time between initial diagnosis and start of
R, was significantly shorter in patients reaching response
(median 322 days; range 7-8964; P=0.008) and CR (237
days; range 29-7726; P=0.042) versus patients without
response (median 783 days; range 23-11487). Vice versa,
comparing 65 patients with ITP for less than one year, with
73 patients with ITP for more than a year, response (57%
vs. 42%) and CR (27% vs. 22%) as well as 2-year RFS (66%
vs. 46%; P=0.06) showed similar tendencies. No synergy
was found between R and (still) having corticosteroids at
study entry, and patient age was not associated with a
higher probability to obtain a response (P=0.25) and RFS
(P=0.57). The total response of 56% with 18 CR, 15 PR and
10 MR in female patients tended to be higher with 41%
response (P=0.08), with 8 CR, 12 PR and 5 MR in males.
Previous splenectomy was present in only 12 patients (with
1 CR, 1 PR and 3 MR) and could thus not be studied as
RMF. In case of non-response or later relapse, patients often
received other treatments. Of these, splenectomy was
specifically studied with only 4 in 68 (6%) initially respond-
ing patients within one year after study initiation. In con-
trast, in the 70 non-responding patients, at least 15 patients
(21%) underwent splenectomy within one year (P=0.01),
while follow up data were not available for 17 of the non-
responding patients. 
Toxicities scored by the NCI Common Terminology
Criteria for Adverse Events (CTCAE; v.3.0), as well as side
effects, were clear and similar in all study arms (Table 3). In
more detail, 22 patients (16%) experienced 23 CTCAE 3 or
4 events; of these, 10 patients (7%) with 10 CTC 3 and 4
events were recorded as SAEs. Another CTC 4 seizure
should have been reported as SAE. As judged by more or
less close occurrence of events to R-administration, and the
absence or presence of other causal factors, 6 of a total 11
events were considered to be probably or possibly treat-
ment-related. Two events were judged to be definitely
related to R-administration (5.7%); all events reversed
without morbidity (Online Supplementary Appendix). 
Our study first of all confirms that lower4 but also more
dense-dosed R are promising therapies for ITP patients.
Interestingly, with 7 of 20 early responding patients receiv-
ing only two once-weekly 375 mg/ m2 doses, arm B did not
lead to inferior results in response quality or RFS. The value
of such a dose sparing strategy should, however, be con-
firmed by a randomized study comparing no or additional
treatment in early responding patients, A second important
issue is that response delays other treatments. In this
respect, 15 of 63 non-responding patients underwent
splenectomy in the first year after study entry, while this
was needed in only 4 of 63 previously non-splenectomized
responders. However, it remains to be determined whether
R can eventually help avoid splenectomy.1,2,5 Of the
response-modulating factors studied in the pooled patients
from all treatment arms, early response and female sex
were associated with more frequent and better responses.12
The latter, although non-significant, is in contrast to a
recent meta-analysis which found male ITP patients to
have a better 1-year response. Age is a complicated
response modulator1 because higher age is associated with
longer disease duration and therapy resistance. In this light,
we could indeed show that responding patients had shorter
disease durations,3 while response, CR and longer CR dura-
tion tended to be superior in patients with an ITP diagnosis
of less than one year. In other studies, up-front corticos-
teroids combined with R12-14 show synergy. We did not
observe this effect, probably due to the fact that only corti-
costeroid-resistant patients were eligible for our study. 
In conclusion, our detailed data can serve as a basis for
future studies; for example, in which R is compared with
other splenectomy-delaying approaches, such as TPO
receptor agonists and splenectomy itself, and which
include cost effectiveness and quality of life outcomes.
Such studies might additionally generate the (immunologi-
cal) predictors to help select the optimal ITP therapy and
identify which patients would benefit most.8,16
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